Last reviewed · How we verify

NCT05279261

Clinical Effect of the Axillary Approach to Glenoid Fractures

Status unknown NA Last updated 15 March 2022
What this trial tests

NA trial testing The axillary approach in Fracture; Glenoid in 15 participants. Status unknown.

Timeline
12 June 2019
Primary endpoint
1 July 2022
1 July 2022

Quick facts

Lead sponsorPeking University Third Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date12 June 2019
Primary completion1 July 2022
Estimated completion1 July 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 80, any sex, with Fracture; Glenoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Glenoid fractures result in glenohumeral post-trauma arthritis and instability. Operative treatment is indicated for severe fractures. The traditional deltopectoral approach, which requires detachment of the subscapularis, has many drawbacks, including loss of external rotation and suboptimal fixation. Arthroscopic techniques also cannot allow anatomic reduction and biomechanical stability for large fractures. We describe an alternative approach that enters from the axilla through the interval between the rotator cuff and the inferior glenoid, neck and lateral border of the scapula without detachment of the rotator cuff.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A novel concealed posterior axillary approach for scapula glenoid fractures - a multicenter clinical study.
    Wang Q, Xing Y, Ding J, Yang D, et al · · 2025 · cited 1× · PMID 40697066 · DOI 10.1097/js9.0000000000002971

Verify or expand the search:

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05279261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing